Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001228416 | SCV001400814 | uncertain significance | CHARGE syndrome | 2024-07-22 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 685 of the SEMA3E protein (p.Asp685Asn). This variant is present in population databases (rs768606535, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SEMA3E-related conditions. ClinVar contains an entry for this variant (Variation ID: 955728). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002497775 | SCV002798193 | uncertain significance | CHARGE syndrome; Hypogonadotropic hypogonadism 7 with or without anosmia | 2022-01-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004032631 | SCV004946942 | uncertain significance | not specified | 2023-12-12 | criteria provided, single submitter | clinical testing | The c.2053G>A (p.D685N) alteration is located in exon 17 (coding exon 17) of the SEMA3E gene. This alteration results from a G to A substitution at nucleotide position 2053, causing the aspartic acid (D) at amino acid position 685 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003918787 | SCV004735625 | uncertain significance | SEMA3E-related disorder | 2023-12-30 | no assertion criteria provided | clinical testing | The SEMA3E c.2053G>A variant is predicted to result in the amino acid substitution p.Asp685Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |